Authorisation of Mpox vaccines and transparency
26.9.2024
Priority question for written answer P-001831/2024
to the Commission
Rule 144
Friedrich Pürner (NI)
On 18 September 2024, during an exchange of views with the Commissioner responsible for health on the EU response to the Mpox virus outbreak, Members of the European Parliament warned that the EU had failed to learn the lessons of the COVID-19 pandemic.
The commitment to ‘protect the ill from harm’ enshrined in the Hippocratic Oath, is a fundamental value that I as a physician feel bound by. Vaccinations can protect, but they can also cause harm. In particular, when a vaccine is not authorised for a specific group of people, or when side effects or harmful effects of vaccines are ignored, as happened in the case of the COVID vaccines.
The EU is donating vaccines to countries affected by the Mpox outbreak. The vaccine is authorised for people aged 12 and over, but there is a lack of data for children, adolescents, pregnant women and immunocompromised people.
In addition, the Court found that the Commission acted in a non-transparent manner in connection with COVID vaccine contracts. This has seriously damaged the EU’s reputation.
- 1.How is it ensured that the vaccine is not administered indiscriminately to the above-mentioned categories of people?
- 2.How can the Commission extend the authorisation of the Mpox vaccine to adolescents if clinical trials are not yet completed?
- 3.What is the Commission doing to ensure greater transparency with regard to the Mpox contracts in light of the debacle associated with the COVID vaccine contracts?
Submitted: 26.9.2024